Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
yNBsapveepWe9FuW
Listen
